Neonatal respiratory distress syndrome (RDS): nursing reference

Respiratory distress syndrome (RDS) is the most common serious lung disorder of the preterm newborn. In the NICHD Neonatal Research Network cohort of infants born at 22–28 weeks, 93% had RDS (Stoll 2010), and in a US cohort of late preterm births the incidence was still 10.5% at 34 weeks, falling to 0.3% at 38 weeks (Hibbard 2010). It is caused by a developmental deficiency of pulmonary surfactant – a lipid-protein mixture that reduces alveolar surface tension and prevents alveolar collapse at end-expiration. Without adequate surfactant, the work of breathing escalates rapidly with each breath, alveoli collapse, gas exchange fails, and hypoxemia progresses to respiratory failure.

This reference covers the pathophysiology, clinical recognition, diagnostic criteria, respiratory support ladder, surfactant replacement therapy, oxygen targeting, complications, and nursing interventions that matter most for NCLEX and NICU practice. It also addresses the 34–36 week transition zone – where RDS risk drops sharply but late preterm infants remain vulnerable – and the distinction between RDS and transient tachypnea of the newborn (TTN), a common NCLEX discriminator.

For the broader context of neonatal assessment and common diagnoses, see the neonatal nursing reference. For resuscitation in the delivery room, see neonatal resuscitation nursing. For the obstetric perspective on preterm birth management including antenatal steroid administration, see preterm labor nursing.

Surfactant deficiency: the core pathophysiology

Pulmonary surfactant is produced by Type II pneumocytes – specialized alveolar epithelial cells that also act as the progenitors of the thin Type I cells lining most of the alveolar surface. Surfactant production begins around 20–24 weeks of gestation but does not reach functionally adequate levels until approximately 34–36 weeks. The primary surface-active component is dipalmitoylphosphatidylcholine (DPPC, a form of lecithin), which – together with other phospholipids such as phosphatidylglycerol and four surfactant-specific proteins (SP-A, SP-B, SP-C, SP-D) – reduces surface tension at the air-liquid interface inside the alveolus.

The relationship between surfactant sufficiency and gestational age is inverse: the younger the infant, the higher the risk. At 24–26 weeks, Type II pneumocytes are still immature and surfactant production is minimal. By 30–32 weeks, production is increasing but storage is limited. The 34–36 week window is the transition zone – most infants at 36 weeks have adequate surfactant, but late preterm infants at 34–35 weeks still carry meaningful RDS risk, particularly after cesarean delivery (which bypasses the catecholamine surge of labor that helps clear lung fluid and stimulate surfactant release).

Without surfactant, surface tension at the alveolar air-liquid interface is high. According to the Law of Laplace (P = 2T/r), the smaller the alveolus, the greater the pressure needed to keep it open, so small alveoli empty into larger ones and collapse first. Surfactant-deficient alveoli collapse at end-expiration (a process called atelectasis), and the infant must generate enormous negative intrathoracic pressure with each breath to re-inflate them from a collapsed state. This is exhausting work for a preterm infant with a compliant chest wall, weak respiratory muscles, and limited glycogen stores. Over the first 6–24 hours, respiratory effort increases progressively, CO2 rises, pH falls, and – without intervention – respiratory failure ensues.

Clinical signs and recognition

RDS presents within the first few hours of life, often in the delivery room. The classic clinical signs reflect the infant’s attempts to maintain alveolar patency and maximize gas exchange under conditions of low lung compliance.

Severity progresses over the first 24–72 hours in untreated RDS. The Silverman-Anderson retraction score or Downes score can be used to grade distress and track trends. After surfactant, oxygenation and compliance often improve within minutes, so the nurse must be ready to wean FiO2 and pressures promptly.

Diagnosis

RDS is a clinical and radiographic diagnosis. No single test is pathognomonic, but the combination of prematurity, clinical signs, and chest X-ray findings is usually definitive.

Chest X-ray (CXR): The classic pattern is ground-glass opacity – a fine, reticular (granular) haziness distributed uniformly across both lung fields. Air bronchograms are visible because the fluid-filled alveoli surrounding air-filled bronchi make the airways visible as dark linear streaks on the hazy background. Severe RDS shows a “white-out” pattern where lung opacity approaches that of the cardiac silhouette, making cardiac borders difficult to distinguish. This CXR pattern, combined with prematurity and clinical signs, supports the diagnosis. Current European guidance places less weight on radiographic grading and blood-gas definitions: surfactant is now given pre-emptively on clinical grounds (work of breathing and oxygen requirement), and lung ultrasound is increasingly used to judge surfactant need (Sweet 2023).

Arterial blood gas (ABG): ABG in RDS shows a combined respiratory and metabolic acidosis. Expect hypoxemia (low PaO2), hypercapnia (elevated PaCO2) due to CO2 retention from alveolar hypoventilation, and acidosis (low pH). As respiratory failure progresses, the metabolic component worsens due to lactic acidosis from hypoperfusion.

SpO2 monitoring: Continuous pulse oximetry is mandatory. For preterm infants receiving oxygen, the AAP suggests a target of 90–95% (Cummings 2016), and the 2022 European consensus targets 90–94% with alarm limits at 89% and 95% (Sweet 2023). Follow your unit’s protocol; the rationale for this narrow band is discussed in the oxygen targeting section below.

Blood cultures: RDS and Group B streptococcal (GBS) pneumonia/sepsis can be clinically and radiographically indistinguishable. When the infant is evaluated for early-onset sepsis, a blood culture is drawn before empiric antibiotics start. The AAP’s 2018 preterm guidance uses a risk-based approach: preterm infants delivered by cesarean for maternal indications without labor, membrane rupture or suspected intra-amniotic infection are at low risk, while those born after preterm labor, ruptured membranes or chorioamnionitis usually receive empiric antibiotics (Puopolo 2018). For neonatal sepsis management principles, see neonatal sepsis nursing.

Respiratory support ladder

Management of RDS follows a stepwise escalation of respiratory support, beginning with the least invasive effective modality. The goal at every step is to maintain adequate oxygenation and ventilation while minimizing barotrauma, volutrauma, and oxygen toxicity.

The key NCLEX teaching point: Nasal CPAP is the first-line respiratory support for a preterm infant with RDS, and intubation is reserved for infants who fail it. The AAP (2014) and the European Consensus Guidelines (Sweet 2023) both support early CPAP with selective surfactant over prophylactic intubation for infants who stabilize on CPAP. Where surfactant is needed in a spontaneously breathing infant, the European guidance prefers LISA/MIST via thin catheter over INSURE, because the infant stays on CPAP throughout.

Surfactant replacement therapy

Exogenous surfactant administration is the cornerstone of RDS treatment. All surfactant preparations available in the US are derived from animal sources (porcine or bovine lung extract) and contain the phospholipids and surfactant proteins (SP-B and SP-C) required for surface tension reduction.

Prophylactic vs. selective (rescue) administration: The older prophylactic strategy – intubating very preterm infants at birth to give surfactant before RDS develops – came from trials run before early CPAP and antenatal steroids were routine. The 2026 Cochrane update (10 trials, 3,151 infants) found that in infants stabilized on CPAP, prophylactic surfactant made little or no difference to chronic lung disease and probably slightly increased mortality, so the authors support CPAP first, then selective surfactant (Beijers 2026). European guidance has recommended selective use since 2013: give surfactant early in the course of RDS when FiO2 exceeds 0.30 on CPAP of at least 6 cmH2O (lower thresholds for the most immature infants), and give it to any infant under 30 weeks who needs intubation for stabilization (Sweet 2023). When surfactant is needed, LISA is preferred where clinicians are experienced; INSURE remains an option, and both avoid prolonged mechanical ventilation.

Administration technique and post-dose nursing actions:

1. Pre-medicate for pain/comfort per unit protocol (surfactant instillation via ETT is uncomfortable).
2. Confirm ETT position with CXR or capnography before dosing.
3. Prepare the product as its label directs. Curosurf is warmed slowly to room temperature; Survanta stands at room temperature for at least 20 minutes (or is warmed in the hand for 8 minutes) with no artificial warming; Infasurf does not need to reach room temperature. Do not shake any of them – invert or swirl gently.
4. Administer as the label directs, usually in divided aliquots, to promote distribution.
5. After dosing, monitor for rapid improvement in lung compliance – this is the most critical immediate post-dose nursing action. As surfactant takes effect, the lungs become more compliant; tidal volumes delivered by the ventilator increase, and if ventilator settings are not adjusted, the infant may develop hyperinflation or barotrauma.
6. ETT displacement risk increases immediately after dosing – the bolus of liquid can shift tube position. Reassess breath sounds bilaterally and monitor SpO2 and CO2 waveform continuously.
7. Avoid routine suctioning after dosing, which can remove the just-instilled medication. Transient rales and moist breath sounds are expected; the Survanta label advises suctioning only for clear signs of airway obstruction. Follow unit policy on how long to wait.

Oxygen targeting: the 90–95% window

Oxygen targeting in preterm infants requires balancing two competing risks. The AAP suggests 90–95% (Cummings 2016); the 2022 European consensus targets 90–94% with alarm limits at 89% and 95% (Sweet 2023).

Hypoxia risk (SpO2 below the target range): Persistent hypoxemia causes pulmonary hypertension, impairs cardiac function, promotes anaerobic metabolism and metabolic acidosis, and – in severe cases – causes end-organ injury to the brain, kidneys, and gut. IVH risk is increased with hypoxic episodes.

Hyperoxia risk (SpO2 >95%): Excess oxygen in the premature lung generates free radicals that injure the developing respiratory epithelium, promoting bronchopulmonary dysplasia (BPD). In the developing retina, hyperoxia causes vasoconstriction of the immature retinal vessels followed by pathological neovascularization – the mechanism behind retinopathy of prematurity (ROP).

Current targets descend from the upper (91–95%) of the two arms tested in the SUPPORT trial, and the reason it won is worth understanding precisely, because the trade-off does not run the way the hyperoxia rationale alone would predict. SUPPORT randomized 1,316 infants born at 24 0/7 to 27 6/7 weeks to either 85–89% or 91–95%. The lower target substantially reduced severe retinopathy among survivors, but it significantly increased mortality before discharge, and the combined outcome of severe ROP or death was no different between the arms. The NeOProM meta-analysis (4,965 infants from SUPPORT, BOOST-II and COT) found no difference in death or major disability at 18–24 months, but the lower target raised death (19.9% vs 17.1%) and severe NEC (9.2% vs 6.9%) while lowering ROP treatment (10.9% vs 14.9%) (Askie 2018). The higher range therefore represents a survival-weighted compromise: it accepts a higher ROP rate in exchange for lower mortality, which is why guidelines caution specifically against drifting the target down into the high 80s to protect the eyes.

The nurse’s role in oxygen targeting is to maintain continuous SpO2 monitoring, respond promptly to alarms in both directions, and communicate FiO2 titration needs to the team. Oxygen is a drug – document FiO2 changes exactly as you would any medication adjustment.

Antenatal corticosteroids

The single most effective intervention for reducing RDS incidence and severity occurs before birth. Antenatal corticosteroids – betamethasone 12 mg IM x2 doses, 24 hours apart, or dexamethasone 6 mg IM x4 doses, 12 hours apart – are recommended by ACOG for pregnant patients at risk of preterm delivery within 7 days between 24 0/7 and 33 6/7 weeks of gestation, and may be considered from 23 0/7 weeks (Committee Opinion 713) or from 22 0/7 weeks when neonatal resuscitation is planned after counseling (ACOG/SMFM practice advisory, 2021). ACOG also recommends a single course of betamethasone in the late preterm window – 34 0/7 to 36 6/7 weeks – for those at risk of delivery within 7 days who have not already had a course, based on the ALPS trial, which cut severe respiratory complications from 12.1% to 8.1% but raised neonatal hypoglycemia (24.0% vs 14.9%). Late preterm infants exposed to steroids therefore need glucose monitoring. ALPS did not study multiple gestations or pregestational diabetes, and a repeat course is not given in the late preterm window.

Mechanism: corticosteroids cross the placenta and bind to glucocorticoid receptors in fetal Type II pneumocytes, accelerating differentiation and surfactant phospholipid synthesis. They also promote lung fluid reabsorption and structural maturation of the alveolar architecture.

Timing matters: The optimal benefit window is 24 hours to 7 days after the first dose. Benefit appears to wane after 7 days, so ACOG advises considering a single repeat course before 34 weeks if the first course was more than 14 days earlier and delivery is again expected within 7 days. A course initiated less than 24 hours before delivery provides some benefit (especially for infants <28 weeks) but is incomplete. When preterm delivery appears imminent, corticosteroids are started immediately – even if delivery might occur within hours – because partial exposure is better than none.

Evidence: In the 2020 Cochrane review (27 trials, 11,925 neonates), antenatal corticosteroids reduced RDS (RR 0.71, high certainty), neonatal death (RR 0.78) and perinatal death (RR 0.85), and probably reduced IVH (RR 0.58) (McGoldrick 2020). The 2020 update dropped six trials that failed new trustworthiness criteria, so it supersedes the 2017 version. This is one of the most robustly supported interventions in perinatal medicine.

Nurses caring for patients at risk of preterm birth should confirm antenatal steroid administration status on admission and advocate for administration if criteria are met but steroids have not been given. For the full obstetric management context, see preterm labor nursing.

Complications of RDS

Infants with RDS – particularly those who are extremely preterm or who require prolonged mechanical ventilation – are at risk for several serious complications.

Bronchopulmonary dysplasia (BPD): The most common chronic complication of RDS. The 2001 NIH consensus definition requires supplemental oxygen for at least 28 days, with severity graded at 36 weeks postmenstrual age for infants born before 32 weeks (or at 56 days of age for those born at 32 weeks or later) (Jobe and Bancalari 2001). The NICHD Neonatal Research Network’s 2019 definition grades BPD by the respiratory support an infant born before 32 weeks needs at 36 weeks postmenstrual age – grade 1 nasal cannula ≤2 L/min, grade 2 cannula >2 L/min or non-invasive positive pressure, grade 3 invasive ventilation – because that best predicted later death or serious respiratory morbidity (Jensen 2019). Caused by a combination of lung immaturity, oxygen toxicity, and ventilator-induced injury (barotrauma and volutrauma). Prevention strategies include gentle ventilation, early CPAP, and targeted surfactant use.

Air leak syndromes: Pulmonary interstitial emphysema (PIE), pneumothorax, pneumomediastinum, and pneumopericardium can all occur when high ventilator pressures or auto-PEEP causes alveolar rupture. PIE – air tracking into the pulmonary interstitium – appears on CXR as linear or cystic lucencies and markedly worsens gas exchange. Pneumothorax presents with sudden deterioration, decreased breath sounds on the affected side, and mediastinal shift. Transillumination of the chest at the bedside and urgent CXR confirm the diagnosis. For a detailed review of pneumothorax management, see pneumothorax nursing.

Intraventricular hemorrhage (IVH): Hemorrhage into the germinal matrix – a highly vascular, fragile subependymal zone present in preterm brains – is a major complication of prematurity. Hypoxia, hypercapnia, rapid fluid shifts, and wide swings in blood pressure all contribute to IVH risk. Grades III and IV IVH carry significant risks of long-term neurodevelopmental impairment. Minimal stimulation protocols, head midline positioning, and careful blood pressure management are nursing priorities.

Necrotizing enterocolitis (NEC): Inflammatory necrosis of the intestinal wall, most common in preterm infants. Hypoxia and hypoperfusion from RDS reduce intestinal perfusion and impair mucosal barrier function, increasing NEC risk. For glucose management in the preterm neonate – a related vulnerability – see neonatal hypoglycemia nursing.

Retinopathy of prematurity (ROP): Pathological retinal neovascularization triggered by hyperoxia (and subsequent relative hypoxia). Severity ranges from mild (spontaneous regression) to severe (retinal detachment and blindness). Prevention relies on strict oxygen targeting with prompt response to high-saturation alarms. Under the 2018 AAP policy, infants with a birth weight of 1,500 g or less or a gestational age of 30 weeks or less are screened, along with selected infants of 1,500–2,000 g or over 30 weeks with an unstable course. The first exam is at 31 weeks postmenstrual age or 4 weeks after birth, whichever is later (Fierson 2018).

Patent ductus arteriosus (PDA): The ductus arteriosus normally closes in response to rising oxygen levels after birth. In preterm infants with hypoxemia, the ductus may remain open, creating a left-to-right shunt that worsens pulmonary congestion and increases ventilator requirements. Many PDAs close on their own, and routine treatment to close the duct is not considered good practice; when a hemodynamically significant PDA is treated, options are ibuprofen, indomethacin or acetaminophen (paracetamol) (Sweet 2023), with surgical ligation or catheter closure reserved for ducts that fail medical therapy. Watch for GI bleeding and reduced urine output with ibuprofen and indomethacin.

RDS vs. TTN: the NCLEX discriminator

Transient tachypnea of the newborn (TTN) is the most common cause of respiratory distress in the term newborn and is frequently tested alongside RDS on NCLEX. Both present with tachypnea and respiratory distress, but the pathophysiology, time course, CXR findings, and management differ substantially.

The key clinical rule for NCLEX: if the question says the baby is getting worse over the first 48–72 hours and has a ground-glass CXR, think RDS. If the baby is getting better by itself on room air or low-flow O2 and was born by cesarean at term, think TTN.

Nursing interventions

Nursing care of an infant with RDS integrates respiratory monitoring, thermoregulation, minimal stimulation, and family support into a coherent bedside approach.

Thermoregulation: Preterm infants have minimal subcutaneous fat, a high surface-area-to-volume ratio, and immature thermoregulatory mechanisms. Cold stress dramatically increases oxygen consumption and worsens acidosis, which further impairs surfactant function. Maintain temperature in a radiant warmer (acute phase) or double-walled isolette (once stable). Target axillary temperature 36.5–37.5°C. For transport within the unit, use pre-warmed transport isolette.

Minimal stimulation: Handling and stimulation increase oxygen consumption and can precipitate hypoxic episodes, bradycardia, and IVH in fragile preterm infants. Cluster care activities – group assessments, blood draws, diaper changes, and position changes – to allow adequate rest between interventions. Post signs at the bedside and communicate the minimal-stimulation plan to all team members and families.

Positioning: Prone positioning improves ventilation-perfusion matching in intubated infants and can reduce the work of breathing; however, prone positioning requires continuous monitoring and is generally used only in the ventilated or continuously monitored setting in the NICU. The nurse is responsible for verifying the rationale and safety checks for each infant’s positioning order.

Work of breathing documentation: At every assessment, document the presence or absence of grunting, nasal flaring, intercostal retractions, subcostal retractions, and suprasternal retractions. Record respiratory rate, oxygen requirement (FiO2), SpO2, and ventilator parameters. Trends across assessments are often more informative than any single data point.

Parental support and skin-to-skin care: The NICU environment is overwhelming for families. Provide consistent, clear explanations of what is happening and why each intervention is in place. Skin-to-skin (kangaroo) care is beneficial once the infant is stable enough by unit criteria – many units offer it on CPAP and some during stable mechanical ventilation – and helps maintain temperature while improving bonding, growth and breastfeeding rates (Sweet 2023). Neonatal jaundice monitoring is also relevant for preterm infants as they transition off respiratory support; see neonatal jaundice nursing.

Sepsis co-management: Because GBS pneumonia mimics RDS clinically and radiographically, infants at risk of early-onset sepsis usually receive empiric ampicillin plus gentamicin, and the AAP advises stopping antibiotics by 36–48 hours of culture incubation if the blood culture is sterile, unless there is a site-specific infection (Puopolo 2018). The nurse draws cultures before antibiotic administration, verifies timing of the first dose, and monitors for culture results that may clarify the diagnosis. See neonatal sepsis nursing for the full sepsis framework.

Connections to adult respiratory nursing: The core concepts of lung compliance, PEEP, FiO2 titration, and oxygen toxicity in RDS parallel those in adult ARDS nursing. The mechanical differences (neonatal lung size, different ventilator modes, surfactant therapy) are substantial, but understanding the shared physiology deepens understanding of both conditions. For community-acquired pneumonia comparison and differential, see pneumonia nursing.

NCLEX tips

These are the highest-yield RDS testing points for NCLEX, covering pathophysiology, clinical recognition, safe oxygen management, and pharmacology.

1. Surfactant deficiency is the primary cause of RDS. Type II pneumocytes produce surfactant, but they are functionally immature before 34–36 weeks of gestation. Infection, retained lung fluid and cardiac disease can mimic RDS, so treat them as differentials rather than causes.

2. The classic CXR pattern is ground-glass opacity with air bronchograms. This bilateral, diffuse, fine granular haziness with visible bronchi on CXR is the radiographic hallmark of RDS. If a question describes this CXR in a preterm infant with respiratory distress, the diagnosis is RDS until proven otherwise.

3. Nasal CPAP is first-line for RDS, and intubation is the fallback. NCLEX frequently tests whether students reach for intubation too early. CPAP maintains alveolar recruitment non-invasively. Intubation is reserved for infants who fail CPAP or who receive surfactant via INSURE; with LISA the infant stays on CPAP.

4. SpO2 target in preterm infants on oxygen is roughly 90–95%. The AAP suggests 90–95%; European guidance uses 90–94% with alarms at 89% and 95%. Saturations above the range raise the risk of ROP and BPD. Saturations below it raise mortality, as the SUPPORT and NeOProM data showed. Know this range cold, and follow your unit’s protocol.

5. Betamethasone given to the mother 24 hours to 7 days before preterm delivery lowers RDS risk by about 29% (Cochrane 2020: RR 0.71) and also reduces neonatal death. It accelerates fetal Type II pneumocyte maturation and surfactant production. NCLEX may ask who receives the drug (the mother, not the infant) and the optimal timing window.

6. After surfactant administration, assess immediately for rapid compliance change. As the surfactant takes effect, the lungs become more compliant and tidal volumes increase. If ventilator settings are not adjusted downward, the infant is at risk for barotrauma and hyperinflation. Also reassess ETT position – the bolus administration can shift the tube.

7. BPD (bronchopulmonary dysplasia) is the most common chronic complication of RDS. For infants born before 32 weeks it is assessed at 36 weeks postmenstrual age (oxygen need, or the level of respiratory support under the 2019 NICHD grading). Caused by a combination of lung immaturity, oxygen toxicity, and ventilator injury. Prevention relies on gentle ventilation, oxygen targeting, and early CPAP.

8. Grunting is physiological PEEP. The infant is exhaling against a partially closed glottis to maintain positive end-expiratory pressure and prevent alveolar collapse. Grunting signals that the infant is working hard to compensate for lung disease. Worsening or louder grunting signals deteriorating respiratory status.

9. RDS risk decreases sharply with each week of gestation. In a US cohort, RDS affected 10.5% of infants born at 34 weeks and 0.3% at 38 weeks (Hibbard 2010). An infant at 38 weeks presenting with respiratory distress is far more likely to have TTN, GBS pneumonia, or another cause than RDS.

10. Distinguish RDS from TTN on the time course and CXR. RDS worsens over the first 24–72 hours without treatment; TTN improves spontaneously. RDS shows ground-glass opacity on CXR; TTN shows perihilar streaking. RDS requires active respiratory support and often surfactant; TTN typically resolves with supplemental oxygen alone. Born by cesarean at term = think TTN first.

For the full neonatal assessment framework, initial stabilization, and NICU orientation content, return to the neonatal nursing reference. For delivery room resuscitation steps, see neonatal resuscitation nursing.

References

1. Sweet DG, Carnielli VP, Greisen G, et al. “European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update.” Neonatology. 2023;120(1):3–23. doi: 10.1159/000528914
2. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. “Target ranges of oxygen saturation in extremely preterm infants.” New England Journal of Medicine. 2010;362(21):1959–1969. doi: 10.1056/NEJMoa0911781
3. Morley CJ, Davis PG, Doyle LW, et al. “Nasal CPAP or intubation at birth for very preterm infants.” New England Journal of Medicine. 2008;358(7):700–708. doi: 10.1056/NEJMoa072788
4. Finer NN, Carlo WA, Walsh MC, et al. “Early CPAP versus surfactant in extremely preterm infants.” New England Journal of Medicine. 2010;362(21):1970–1979. doi: 10.1056/NEJMoa0911783
5. Jobe AH. “Mechanisms of lung injury and bronchopulmonary dysplasia.” American Journal of Perinatology. 2016;33(11):1076–1078. doi: 10.1055/s-0036-1586107
6. Liggins GC, Howie RN. “A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants.” Pediatrics. 1972;50(4):515–525.
7. McGoldrick E, Stewart F, Parker R, Dalziel SR. “Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.” Cochrane Database of Systematic Reviews. 2020;12(12):CD004454. doi: 10.1002/14651858.CD004454.pub4 (supersedes Roberts 2017, CD004454.pub3)
8. Stoll BJ, Hansen NI, Bell EF, et al. “Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network.” Pediatrics. 2010;126(3):443–456. doi: 10.1542/peds.2009-2959
9. American Academy of Pediatrics Committee on Fetus and Newborn. “Respiratory support in preterm infants at birth.” Pediatrics. 2014;133(1):171–174. doi: 10.1542/peds.2013-3442
10. Abdel-Latif ME, Davis PG, Wheeler KI, De Paoli AG, Dargaville PA. “Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome.” Cochrane Database of Systematic Reviews. 2021;5(5):CD011672. doi: 10.1002/14651858.CD011672.pub2
11. Beijers RJHCG, Alonso-Fernández S, Soll RF, Rojas-Reyes MX. “Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants at risk of respiratory distress syndrome.” Cochrane Database of Systematic Reviews. 2026;7(7):CD000510. doi: 10.1002/14651858.CD000510.pub3
12. Horbar JD, Carpenter JH, Badger GJ, et al. “Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009.” Pediatrics. 2012;129(6):1019–1026. doi: 10.1542/peds.2011-3028
13. Polin RA, Carlo WA; Committee on Fetus and Newborn. “Surfactant replacement therapy for preterm and term neonates with respiratory distress.” Pediatrics. 2014;133(1):156–163. doi: 10.1542/peds.2013-3443
14. Vaucher YE, Peralta-Carcelen M, Finer NN, et al. “Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial.” New England Journal of Medicine. 2012;367(26):2495–2504. doi: 10.1056/NEJMoa1208506
15. Bancalari E, Jain D. “Bronchopulmonary dysplasia: 50 years after the original description.” Neonatology. 2019;115(4):384–391. doi: 10.1159/000497422
16. Askie LM, Darlow BA, Finer N, et al.; Neonatal Oxygenation Prospective Meta-analysis (NeOProM) Collaboration. “Association between oxygen saturation targeting and death or disability in extremely preterm infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration.” JAMA. 2018;319(21):2190–2201. doi: 10.1001/jama.2018.5725
17. Consortium on Safe Labor; Hibbard JU, Wilkins I, Sun L, et al. “Respiratory morbidity in late preterm births.” JAMA. 2010;304(4):419–425. doi: 10.1001/jama.2010.1015
18. Cummings JJ, Polin RA; Committee on Fetus and Newborn. “Oxygen targeting in extremely low birth weight infants.” Pediatrics. 2016;138(2):e20161576. doi: 10.1542/peds.2016-1576
19. Fierson WM; American Academy of Pediatrics Section on Ophthalmology, et al. “Screening examination of premature infants for retinopathy of prematurity.” Pediatrics. 2018;142(6):e20183061. doi: 10.1542/peds.2018-3061
20. Puopolo KM, Benitz WE, Zaoutis TE; Committee on Fetus and Newborn, Committee on Infectious Diseases. “Management of neonates born at ≤34 6/7 weeks’ gestation with suspected or proven early-onset bacterial sepsis.” Pediatrics. 2018;142(6):e20182896. doi: 10.1542/peds.2018-2896
21. Jobe AH, Bancalari E. “Bronchopulmonary dysplasia.” American Journal of Respiratory and Critical Care Medicine. 2001;163(7):1723–1729. doi: 10.1164/ajrccm.163.7.2011060
22. Jensen EA, Dysart K, Gantz MG, et al. “The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach.” American Journal of Respiratory and Critical Care Medicine. 2019;200(6):751–759. doi: 10.1164/rccm.201812-2348OC
23. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. “Committee Opinion No. 713: Antenatal corticosteroid therapy for fetal maturation.” Obstetrics & Gynecology. 2017;130(2):e102–e109 (interim update). doi: 10.1097/AOG.0000000000002237
24. American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine. “Practice Advisory: Use of antenatal corticosteroids at 22 weeks of gestation.” September 2021. acog.org
25. Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. “Antenatal betamethasone for women at risk for late preterm delivery.” New England Journal of Medicine. 2016;374(14):1311–1320. doi: 10.1056/NEJMoa1516783
26. US prescribing information (DailyMed): CUROSURF (poractant alfa), rev. December 2025; INFASURF (calfactant), rev. April 2026; SURVANTA (beractant), rev. March 2024. Accessed 5 October 2026.